Protein transduction domain, fusion compound containing the same, and pharmaceutical composition containing the fusion compound
US11661464B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2020 |
| Grant date | May 30, 2023 |
| Priority date | — |
| Expiry date | May 12, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A protein transduction domain and a fusion compound, which are more efficient, are proposed. As a result of selecting and testing a number of candidate peptides, the present inventors found that a GK1 peptide comprising 18 amino acids and a modified sequence obtained by replacing, adding, or deleting some sequences are bonded to high-molecular-weight materials such as proteins based on the basic sequence of the peptide, thus enabling the high-molecular-weight materials to smoothly penetrate into living bodies, for example, cells, tissues, or blood. A fusion compound, oligonucleotide, or vector using the same may be applied as a pharmaceutical composition for preventing or treating diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.